News >

Future of Immunotherapy in Head and Neck Cancer May Be in Combinations

Angelica Welch
Published: Monday, May 22, 2017

Ezra Cohen, MD

Ezra Cohen, MD

Immunotherapy has become a key player in head and neck cancer with the approvals of pembrolizumab (Keytruda) and nivolumab (Opdivo) this past year. Researchers are hoping to build on the success of the KEYNOTE-012 and CheckMate-141 trials, which led to the approvals of pembrolizumab and nivolumab, respectively, by examining anti–PD-1/PD-L1 agents in the frontline and as a part of combination regimens.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication